Abstract
Our originally developed bedside-type artificial endocrine pancreas system enables the perfect glycemic normalization in diabetics against various stimulations on moment-to-moment basis. However, the size of the device and the vascular access for glucose monitoring make the long-term clinical uses difficult. A needle-type glucose sensor consisted of immobilized glucose oxidase and the electrode, has been developed as the breakthrough for the completion of the wearable-type artificial endocrine pancreas. The successful blood glucose control in depancreatized dogs with this device suggested the feasibility of this closed-loop control system in long-term clinical applications.
